Public Employees Retirement System of Ohio Grows Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT)

Public Employees Retirement System of Ohio boosted its stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT) by 236.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 111,716 shares of the company’s stock after buying an additional 78,513 shares during the quarter. Public Employees Retirement System of Ohio owned 0.14% of Editas Medicine worth $142,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Editas Medicine by 30.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,170,000 shares of the company’s stock worth $1,486,000 after acquiring an additional 272,467 shares during the period. Two Sigma Advisers LP boosted its position in Editas Medicine by 46.8% during the fourth quarter. Two Sigma Advisers LP now owns 1,657,000 shares of the company’s stock worth $2,104,000 after purchasing an additional 528,000 shares in the last quarter. Two Sigma Investments LP grew its holdings in Editas Medicine by 21.4% in the fourth quarter. Two Sigma Investments LP now owns 1,649,072 shares of the company’s stock valued at $2,094,000 after purchasing an additional 290,483 shares during the last quarter. Tang Capital Management LLC purchased a new position in shares of Editas Medicine in the fourth quarter valued at $508,000. Finally, Nuveen Asset Management LLC raised its stake in shares of Editas Medicine by 23.7% during the 4th quarter. Nuveen Asset Management LLC now owns 316,614 shares of the company’s stock worth $402,000 after buying an additional 60,583 shares during the last quarter. 71.90% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Editas Medicine

In related news, CEO Gilmore Neil O’neill sold 15,192 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $1.72, for a total transaction of $26,130.24. Following the completion of the sale, the chief executive officer now owns 280,282 shares of the company’s stock, valued at approximately $482,085.04. This represents a 5.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 16,364 shares of company stock worth $28,146 in the last quarter. 2.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages recently commented on EDIT. Robert W. Baird lowered their price objective on shares of Editas Medicine from $8.00 to $4.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 13th. HC Wainwright started coverage on shares of Editas Medicine in a research note on Monday, April 28th. They set a “buy” rating and a $3.00 price objective for the company. Wall Street Zen upgraded Editas Medicine from a “sell” rating to a “hold” rating in a research report on Wednesday, May 14th. Finally, Cantor Fitzgerald raised Editas Medicine from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 29th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating, two have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $5.36.

Editas Medicine Trading Down 1.1%

Editas Medicine stock opened at $1.80 on Friday. The stock has a fifty day moving average price of $1.45 and a 200 day moving average price of $1.53. Editas Medicine, Inc. has a 52 week low of $0.91 and a 52 week high of $6.22. The firm has a market capitalization of $150.68 million, a P/E ratio of -0.70 and a beta of 2.15.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.08. Editas Medicine had a negative net margin of 340.96% and a negative return on equity of 80.13%. The business had revenue of $4.66 million for the quarter, compared to analyst estimates of $0.79 million. During the same period in the prior year, the firm posted ($76.00) EPS. As a group, equities analysts predict that Editas Medicine, Inc. will post -2.71 EPS for the current year.

Editas Medicine Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.